Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

687 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
How wound environments trigger the release from Rifampicin-loaded liposomes.
Wallenwein CM, Ashtikar M, Hofhaus G, Haferland I, Thurn M, König A, Pinter A, Dressman J, Wacker MG. Wallenwein CM, et al. Among authors: pinter a. Int J Pharm. 2023 Feb 25;633:122606. doi: 10.1016/j.ijpharm.2023.122606. Epub 2023 Jan 9. Int J Pharm. 2023. PMID: 36632921
[No title available]
[No authors listed] [No authors listed] PMID: 38857106
Efficacy and safety of guselkumab in European patients with palmoplantar pustulosis: A multi-center, single-arm clinical trial (GAP study).
Wilsmann-Theis D, Patt S, Pinter A, Gerdes S, Magnolo N, Németh R, Schmitz J, Paul C, Augustin M, Staubach P, Weyergraf A, Hüffmeier U, Wolk K, Sabat R, Mößner R. Wilsmann-Theis D, et al. Among authors: pinter a. JAAD Int. 2024 Oct 2;18:69-78. doi: 10.1016/j.jdin.2024.09.001. eCollection 2025 Feb. JAAD Int. 2024. PMID: 39618912 Free PMC article.
Bimekizumab Efficacy in High-Impact Areas: Pooled 2-Year Analysis in Scalp, Nail, and Palmoplantar Psoriasis from Phase 3/3b Randomized Controlled Trials.
Merola JF, Gottlieb AB, Pinter A, Elewski B, Gooderham M, Warren RB, Piaserico S, Wixted K, Cross N, Tilt N, Wiegratz S, Mrowietz U. Merola JF, et al. Among authors: pinter a. Dermatol Ther (Heidelb). 2024 Dec;14(12):3291-3306. doi: 10.1007/s13555-024-01295-w. Epub 2024 Nov 22. Dermatol Ther (Heidelb). 2024. PMID: 39578348 Free PMC article.
Efficacy and Safety of Risankizumab in Patients with Psoriasis Showing Suboptimal Response to Secukinumab or Ixekizumab: Results from a Phase 3b, Open-Label, Single-Arm (aIMM) Study.
Warren RB, Pavlovsky L, Costanzo A, Bukhalo M, Korman NJ, Huang YH, Kokolakis G, Pinter A, Ibrahim N, Zheng Y, Drogaris L, Stakias V, Soliman AM, Rubant S, Thaçi D. Warren RB, et al. Among authors: pinter a. Dermatol Ther (Heidelb). 2024 Dec;14(12):3273-3290. doi: 10.1007/s13555-024-01292-z. Epub 2024 Nov 8. Dermatol Ther (Heidelb). 2024. PMID: 39516454 Free PMC article.
Urine lipoarabinomannan concentrations among HIV-negative adults with pulmonary or extrapulmonary tuberculosis disease in Vietnam.
Hoa NB, Fajans M, Nguyen Van H, Vu Ngoc B, Nguyen Viet N, Nguyen Thi H, Thi Huong LT, Tran Minh D, Nguyen Kim C, Thi Tuyet TH, Huu TN, Bui Ngoc D, Nguyen Viet H, Khanh AT, Lillis L, Perez M, Thomas KK, Peck RB, Cantera JL, Murphy E, Halas OR, Storey HL, Pinter A, Ruhwald M, Drain PK, Boyle DS. Hoa NB, et al. Among authors: pinter a. PLOS Glob Public Health. 2024 Nov 6;4(11):e0003891. doi: 10.1371/journal.pgph.0003891. eCollection 2024. PLOS Glob Public Health. 2024. PMID: 39504319 Free PMC article.
Antibody-Fab and -Fc features promote Mycobacterium tuberculosis restriction.
Grace PS, Peters JM, Sixsmith J, Lu R, Luedeman C, Fenderson BA, Vickers A, Slein MD, Irvine EB, McKitrick T, Wei MH, Cummings RD, Wallace A, Cavacini LA, Choudhary A, Proulx MK, Sundling C, Källenius G, Reljic R, Ernst JD, Casadevall A, Locht C, Pinter A, Sasseti CM, Bryson BD, Fortune SM, Alter G. Grace PS, et al. Among authors: pinter a. bioRxiv [Preprint]. 2024 Oct 11:2024.10.07.617070. doi: 10.1101/2024.10.07.617070. bioRxiv. 2024. PMID: 39416184 Free PMC article. Preprint.
687 results